Secondary analysis of a phase 3 trial (203 randomised) in HER2+ localised oesophageal adenocarcinoma: adding trastuzumab to chemoradiation and surgery did not significantly increase oesophageal symptom score improvement at 6-8 weeks (46% vs 38%; p=0.39; 108 analysed).
Secondary analysisn = 203
Kachnic et al. Patient-reported outcomes in NRG Oncology RTOG 1010: Phase 3 trial evaluating the addition of trastuzumab to trimodality treatment of HER2 overexpressing esophageal adenocarcinoma